FAQ on Quantum BioPharma Ltd. (NASDAQ: QNTM) Appointment of Kevin Malone as Board Advisor
Summary
Quantum BioPharma Ltd. has appointed Kevin Malone, a seasoned financial advisor and anti-corruption advocate, as a Board Advisor, aligning with its shareholder protection values and therapeutic focus.
Who is Kevin Malone and what is his role at Quantum BioPharma Ltd.?
Kevin Malone is a seasoned financial advisor with over 40 years of family experience in wealth management, known for his work in market pattern recognition and his stance against trading manipulation. He has been appointed as an advisor to the Board of Directors of Quantum BioPharma Ltd., aligning with the company’s shareholder protection values.
What is Quantum BioPharma Ltd. focused on?
Quantum BioPharma Ltd. is a biopharmaceutical company dedicated to developing innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in various stages of development.
What is Lucid-MS and who is developing it?
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It is being developed by Lucid Psycheceuticals Inc., a wholly owned subsidiary of Quantum BioPharma Ltd.
What is UNBUZZD and how is Quantum BioPharma Ltd. involved with it?
UNBUZZD is a product invented by Quantum BioPharma Ltd., which has spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains ownership of 25.71% of Celly Nutrition and receives royalty payments from sales of UNBUZZD.
Where can I find more information about Quantum BioPharma Ltd.?
The latest news and updates relating to Quantum BioPharma Ltd. (QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.
What is BioMedWire and how is it related to this news?
BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It published the press release about Kevin Malone’s appointment as an advisor to Quantum BioPharma Ltd.’s Board of Directors.
What are the terms of the agreement between Quantum BioPharma Ltd. and Celly Nutrition Corp. regarding UNBUZZD?
The agreement includes royalty payments of 7% of sales from UNBUZZD to Quantum BioPharma Ltd. until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 120689